CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it has named Joseph Johnston as Vice President, Regulatory Affairs. Mr. Johnston brings to Catabasis over 25 years of pharmaceutical industry experience.
“Joe brings to Catabasis deep regulatory expertise including experience with orphan and pediatric diseases,” said Joanne Donovan, M.D., Ph.D., Chief Medical Officer of Catabasis. “He is an excellent addition to our executive management team as we progress edasalonexent (CAT-1004) for the treatment of Duchenne muscular dystrophy (DMD).”
“I am very pleased to have the opportunity to bring my regulatory experience to Catabasis and join a company that is committed to making a meaningful impact for the patients and families affected by DMD,” commented Mr. Johnston.
Prior to joining Catabasis, Mr. Johnston was at Ionis Pharmaceuticals (formerly Isis Pharmaceuticals), a biopharmaceutical company in RNA-targeted drug discovery and development, where he served as Vice President, Regulatory Affairs and Quality from 2008 to May 2016. Previously, Mr. Johnston held a series of roles with increasing responsibility at Isis Pharmaceuticals from 1990, when he was part of the original scientific team, to 2008. In his time at Ionis Pharmaceuticals, Mr. Johnston provided global regulatory leadership on hundreds of regulatory applications including experience with rare diseases as well as pediatric indications. Mr. Johnston holds a M.B.A. from University of California Irvine and a M.S. in Pharmacology and a B.A. in Biology, both from the University of Pennsylvania.
About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our SMART (Safely Metabolized And Rationally Targeted) linker drug discovery platform enables us to engineer molecules that simultaneously modulate multiple targets in a disease. We are applying our SMART linker platform to build an internal pipeline of product candidates for rare diseases and plan to pursue partnerships to develop additional product candidates. For more information on the Company's drug discovery platform and pipeline of drug candidates, please visit www.catabasis.com.
